Page 49 - ITPS-6-1
P. 49

43    INNOSC Theranostics and Pharmacological Sciences, 2023, Vol. 6, No. 1                    Hariharan
           care in the  African countries.  Availability,       SCA patients in lower- and lower middle-income
           accessibility,  and  affordability  of  the  diagnostic   regions. Diagnostic  and intervention  packages
           and therapeutic  care in Europe may improve          targeting these patients should be developed  and
           the  survival  of the  patients,  thereby  showing a   implemented  by clinicians  across the  high-risk
           comparatively  higher  prevalence  in the  region.   settings. Further  studies  on  exploring  the  factors

           Hence, there is a need to close the gap in providing   responsible for high burden of PHT among
           care  for the SCA patients between  Europe and       SCA patients  should  be  done  as  it  will  help  the
           Africa. This calls for the development of simple,    clinicians  to understand the mechanism  and take
           non-invasive, and cost-effective tools for screening   decisive  actions  and  implement  patient-specific
           the patients, as it ultimately leads to early diagnosis   interventions accordingly.
           and adequate management of the condition. Using
           right heart catheterization as a screening tool is not   Acknowledgments
           practically  possible due to lack of trained/skilled   None.
           human  resources  in  such low-income/high-SCA-
           burden countries in Africa. TRV screening can be     Funding
           considered a more pragmatic option for screening
           the SCA patients for PHT in such settings. There is   None.
           also availability of many biomarkers that suggest
           the presence of PHT and can be used as an effective   Conflict of interest
           screening tool [54].                                 The author declares no conflicts of interests.
              The major strength of the study is that this is
           so  far  the  first  comprehensive  review  on  burden   Author contributions
           of PHT among the younger population with SCA
           globally.  We  have  also  included  large  number   This is single-authored manuscript.
           of studies  to provide  reasonable  estimate  on     Ethics approval and consent to participate
           the burden. However, our review had certain
           limitations.  All the  included  studies have  used   Not applicable.
           TRV to diagnose PHT. This can overestimate the
           prevalence as the right heart catheterization is the   Consent for publication
           gold standard for diagnosing a case of PHT. The
           Chi-square test for heterogeneity  also revealed     Not applicable.
           significant variability across the included studies.   Availability of data
           This limitation  was overcome  in this work by
           conducting meta-regression to explain the between-   Not applicable.
           study variability using meta-regression and identify
           the potential sources of heterogeneity. Significant   References
           publication bias was also found, indicating that the   [1]   World  Health  Organization.  Sickle-Cell  Disease  and  Other
           point estimate obtained in our review should be             Haemoglobin  Disorders  WHO,  Geneva. Available  from:  https://
           interpreted with caution.                                   apps.who.int/iris/bitstream/handle/10665/20890/A59_9-en.
                                                                       pdf?sequence=1&Isallowed=y [Last accessed on 2022 Feb 11].
           5. Conclusions                                       [2]    World Health Organization. Sickle-Cell Disease. WHO, Geneva.
                                                                       Available  from:  https://www.afro.who.int/health-topics/sickle-
                                                                       cell-disease [Last accessed on 2021 Feb 11].
           Current  review  provides  important  baseline       [3]    Gladwin,  M.T.  Current  and  Future  Therapies  of  Sickle  Cell
           information  on the  epidemiology  of PHT among             Anaemia:  An  Historical  Perspective.  Hematology  Am.  Soc.
                                                                       Hematol. Educ. Program, 2018, 176, 417–9.
           children and adolescents with SCA in the world.      [4]    Haque,  A.K.;  Gokhale,  S.;  Rampy,  B.A.;  Adegboyega,  P.;
           The findings of this systematic review highlight that       Duarte, A.; Saldana, M.J. Pulmonary Hypertension in Sickle Cell
           PHT is one of the important complications among             Hemoglobinopathy: A Clinicopathologic Study of 20 Cases. Hum.
                                                                       Pathol., 2002, 33, 1037–43.
           SCA patients irrespective of their age. This review   [5]   Rother,  R.P.;  Bell,  L.;  Hillmen,  P.;  Gladwin,  M.T.  The  Clinical
           also  highlights  the  fact  that  only  fewer  studies     Sequelae  of  Intravascular  Hemolysis  and  Extracellular  Plasma
                                                                       Hemoglobin:  A  Novel  Mechanism  of  Human  Disease.  JAMA,
           have  investigated  the  extent  of  PHT  among  the        2005, 293, 1653–62.

                                                    ©2023 AccScience Publishing
   44   45   46   47   48   49   50   51   52   53   54